Last reviewed · How we verify
LY3372993
At a glance
| Generic name | LY3372993 |
|---|---|
| Also known as | Remternetug |
| Sponsor | Eli Lilly and Company |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study of Remternetug (LY3372993) in Healthy Chinese Participants (PHASE1)
- A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation (PHASE2, PHASE3)
- A Study of Remternetug (LY3372993) in Healthy Participants (PHASE1)
- A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3) (PHASE3)
- A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1) (PHASE3)
- A Study of LY3372993 in Participants With Alzheimer's Disease (AD) and Healthy Participants (PHASE1)
- A Study of LY3372993 in Healthy Participants and Participants With Alzheimer's Disease (AD) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LY3372993 CI brief — competitive landscape report
- LY3372993 updates RSS · CI watch RSS
- Eli Lilly and Company portfolio CI